Fig. 3

Survival and clinical characteristics of patients with polymerase mutations colorectal [38], endometrial (UCEC) and stomach (STAD) cancers. a Kaplan-Meier curves of Disease-Free Survival (DFS) for 3 groups of patients: POLE only (n = 21, median follow-up =18.4 months), green line; E/Q (n = 6, median follow-up = 19.0 months), orange line; E/Z (n = 9, median follow-up = 34.3 months), pink line, and E/Q/Z (n = 16, median follow-up = 37.5 months), blue line; tumors without mutations in POLE, POLQ or REV3L exomes, grey line. The overall p-value is p = 0.0477. Individual p-values: E/Q/Z vrs. POLE – p = 0.021; E/Q/Z vrs. None – p = 0.018, E/Q or E/Z or E/Q/Z vrs. POLE – p = 0.003. b Polymerase mutation analysis of cases in the good survival group in panel A. The red bar indicates cases with POLE exonuclease mutations. c Cancer type-specific illustration of mutation count, POLE, POLQ and REV3L mutations, microsatellite instability (MSI) and tumor stage